Yield10 Bioscience, Inc. is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa (Camelina) as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and PHA bioplastics for use as biodegradable bioplastics. The Company is pursuing Camelina seed oil products for two market opportunities and value chains. The first product is seed oil produced by Camelina, which is genetically engineered to enable production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). The second product is Camelina seed oil for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD) and sustainable aviation fuel (SAF).

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-03-03	- $	-	2
26-02-27	- $	-	20

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 02:58:13 2026-02-18 pm EST			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	-

25-10-31	Yield10 Bioscience, Inc. Went Out of Business	CI
25-10-14	First Amended Joint Liquidation Plan Approved for Yield10 Bioscience, Inc.	CI

Capitalization	229K 198K 178K 171K 312K 21.06M 327K 2.11M 845K 10.1M 860K 842K 36.12M	P/E ratio 2022	-0.6x	P/E ratio 2023	-0.13x
Enterprise value	2.34M 2.02M 1.82M 1.75M 3.19M 215M 3.33M 21.52M 8.62M 103M 8.78M 8.59M 369M	EV / Sales 2022	14.6x	EV / Sales 2023	83x
Free-Float	85.78%	Yield 2022 *	-	Yield 2023	-

25-10-31	Yield10 Bioscience, Inc. Went Out of Business	CI
25-10-14	First Amended Joint Liquidation Plan Approved for Yield10 Bioscience, Inc.	CI
25-08-20	First Amended Disclosure Statement Approved for Yield10 Bioscience, Inc.	CI
25-08-18	First Amended Joint Liquidation Plan and Disclosure Statement Filed by Yield10 Bioscience, Inc.	CI
25-07-10	Joint Liquidation Plan and Disclosure Statement Filed by Yield10 Bioscience, Inc.	CI
25-01-07	Motion for Asset Sale Approved for Yield10 Bioscience, Inc.	CI
24-12-09	Motion for Joint Administration Approved for Yield10 Bioscience, Inc.	CI
24-12-06	Yield10 Approves Wind Down of Operations and Corresponding Reduction in Workforce	CI
24-12-06	Yield10 Bioscience, Inc. Announces Board Changes	CI
24-12-06	Motion for Asset Sale Filed by Yield10 Bioscience, Inc.	CI
24-12-06	Yield10 Bioscience, Inc. Filed for Bankruptcy	CI
24-12-05	Motion for Joint Administration Filed by Yield10 Bioscience, Inc.	CI
24-11-11	Yield10 Bioscience, Inc. announced that it has received $3 million in funding	CI

24-02-08	Lake Street Downgrades Yield10 Bioscience to Hold From Buy, Cuts Price Target to $0.50 From $3	MT
23-08-17	HC Wainwright Adjusts Price Target on Yield10 Bioscience to $4 From $25, Keeps Buy Rating	MT
22-05-03	Univest Initiates Coverage of Yield10 Bioscience With Buy Rating, $5 Price Target	MT
22-05-03	Univest Securities Starts Yield10 Bioscience at Buy With $5 Price Target	MT
22-04-21	Lake Street Initiates Yield10 Bioscience at Buy with $12 Price Target	MT

Yield10 Bioscience, Inc. Stock

Equities

YTENQ

US98585K8541

Biotechnology & Medical Research

Valuation: Yield10 Bioscience, Inc.

Chart: Yield10 Bioscience, Inc.

Latest news: Yield10 Bioscience, Inc.

Analysts' recommendations: Yield10 Bioscience, Inc.

Press Releases: Yield10 Bioscience, Inc.

Course Extremes

Managers and Directors: Yield10 Bioscience, Inc.

ETFs: Yield10 Bioscience, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

24-11-12	Yield10 Bioscience : Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals; Special Meeting Adjourned to Thursday, November 14, 2024 Form 8 K	PU
24-08-14	Yield10 Bioscience Announces Second Quarter 2024 Financial Results	AQ
24-07-17	Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets	AQ
24-06-17	Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina	AQ
24-06-12	Yield10 Bioscience : Certificate of Incorporation/Bylaws Form 8 K	PU

1 month	0		0
Current year	0		0
1 year	0		0.02
3 years	0		78.96
5 years	0		410.4
10 years	0		21,983.97

Manager	Title	Age	Since
Oliver Peoples CEO	Chief Executive Officer	68	2016-10-16
Charles Haaser DFI	Director of Finance/CFO	70	2014-11-02

Director	Title	Age	Since
Oliver Peoples BRD	Director/Board Member	68	2009-07-06
Robert van Nostrand CHM	Chairman	69	2011-11-07
Richard Hamilton BRD	Director/Board Member	63	2017-03-01

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
YIELD10 BIOSCIENCE, INC.	-.--%	-.--%	-99.33%	-100.00%	73
LONZA GROUP AG	-2.02%	-5.97%	-10.82%	-8.73%	45.49B
BEONE MEDICINES AG	+2.79%	-5.01%	+21.88%	+30.07%	33.41B
CELLTRION, INC.	+0.47%	-10.90%	+20.11%	+49.32%	31.32B
IQVIA HOLDINGS INC.	-2.25%	-2.42%	-8.94%	-17.92%	29.29B
REVOLUTION MEDICINES, INC.	-1.24%	-3.55%	+150.96%	+300.16%	19.5B
ASCENDIS PHARMA A/S	+1.39%	+3.06%	+65.12%	+114.39%	14.77B
MEDPACE HOLDINGS, INC.	+0.26%	+4.17%	+41.40%	+136.11%	13.36B
EUROFINS SCIENTIFIC SE	-1.64%	-5.25%	+25.74%	+6.22%	13.21B
IONIS PHARMACEUTICALS, INC.	-1.49%	-8.76%	+118.99%	+107.63%	12.23B
Average	-0.37%	-3.32%	+32.51%	+61.72%	21.26B
Weighted average by Cap.	-0.42%	-4.59%	+32.27%	+58.27%

	2022	2023
Net sales	450K 388K 350K 336K 613K 41.36M 641K 4.14M 1.66M 19.83M 1.69M 1.65M 70.93M	60K 51.73K 46.7K 44.81K 81.71K 5.51M 85.51K 552K 221K 2.64M 225K 220K 9.46M
Net income	-13.57M -11.7M -10.56M -10.13M -18.47M -1.25B -19.33M -125M -50.01M -598M -50.91M -49.83M -2.14B	-14.46M -12.46M -11.25M -10.8M -19.68M -1.33B -20.6M -133M -53.28M -637M -54.25M -53.09M -2.28B
Net Debt	-1.7M -1.46M -1.32M -1.27M -2.31M -156M -2.42M -15.61M -6.26M -74.79M -6.37M -6.23M -267M	2.11M 1.82M 1.64M 1.58M 2.87M 194M 3.01M 19.41M 7.78M 92.99M 7.92M 7.75M 333M